ClinicalTrials.gg

Muscle Spasticity clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 624 studies for Muscle Spasticity across more than 10 countries. 130 are recruiting or about to start. 197 of them are mainly about Muscle Spasticity (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

ClinicalTrials.gov finds 923 studies for Muscle Spasticity. How that becomes 621 here

This page counts the studies the registry files under Muscle Spasticity, and those it files under no condition that list Muscle Spasticitythemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 923Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −302Match it another way5 name it in the title, 3 in a keyword, and 294 by a synonym or other text the search reads.
  3. 621The count on this page

Status

Completed
368
Recruiting
88
Status unknown
62
Terminated
32
Not yet recruiting
31
Active, not recruiting
18

Phase

Phase 3
64
Phase 2
51
Phase 4
31
Phase 1
25
Early Phase 1
8

Where

United States
165
Turkey
79
France
40
Spain
37
Pakistan
34
Canada
30

Who develops what

Add Muscle Spasticity to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 2 programs from 2 companies, 1 with this as their studies’ main aim; 0 with a live phase 3 study; 1 primary completion in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
botulinum toxin type AEarlier only
Evidence
  • NCT04752774 · Ipsen · Phase 2 · live · background · “Dysport” · registered Feb 2021
  • NCT01915459 · hugel · Phase 3 · comparator · “Botulinum toxin type A(Botox®)” · registered Aug 2013
AbbVie28% of its industry studiesUS: AbbVie (FDA 1991) + 4 othersEU: Evolus, Inc. (EMA 2019)00 studies
BaclofenEarlier only
Evidence
  • NCT01743651 · RVL Pharmaceuticals, Inc. · Phase 3 · comparator · “baclofen” · registered Nov 2012
  • NCT00914290 · Amneal Pharmaceuticals, Inc. · Phase 2 · background · “Baclofen IR” · registered Jun 2009
Viatris Inc.13% of its industry studiesUS: off-patent, 18 generics marketed00 studies

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 2 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 26 May 2027 est.irafamdastat · Bristol-Myers Squibb · Phase 2 main aimNCT06782490 A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity — primary endpoint: Change from baseline in Total Numeric-transformed Modified Ashworth Scale-Most Affected Lower Limb (TNmAS-MALL) score · 200 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Muscle Spasticity studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Coming up

38studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest

Who these studies take

Of the 88 Muscle Spasticity studies recruiting now, 29 (33%) set no upper age limit and 47 (53%) stop at 75 or younger. 34 (39%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 11 (13%) take healthy volunteers.

Recruiting studies that take each age, of 88
AgeWomenMen
1028 (32%)28 (32%)
1865 (74%)65 (74%)
3058 (66%)58 (66%)
4058 (66%)58 (66%)
5060 (68%)60 (68%)
6555 (63%)55 (63%)
7547 (53%)47 (53%)
8535 (40%)35 (40%)

Across all 622 studies, recruiting or not: 46% stop at 75 or younger and 33% at 65; 28% take children; <1% are for women only and <1% for men only; 11% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Muscle Spasticity studies take

Of 16 phase 3 interventional studies under Muscle Spasticity, half reached primary completion within 33 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 333 mo16–57 · 16 studies——
Interventional, no phase15 mo7–34 · 234 studies—15 mo6–37 · 226 studies
Observational32 mo9–124 · 59 studies—23 mo9–… · 54 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 624. Browse all 624 → or search them.